Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from TMBR

The Worst Biotech Stocks Investors Could Buy This Fall

Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak fundamentals, the stock could be a poor choice for investors enticed by its negligible price. Let’s discuss….

StockNews.com · Nov 1, 2022

4 Stocks That Have Taken a Turn for the Worse in 2022

The Fed’s hawkish stance on inflation has raised the likelihood of a recession in the near term. Fundamentally weak stocks Marvell Technology (MRVL), Plug Power (PLUG), Riot Blockchain (RIOT), and Timber Pharmaceuticals (TMBR) have plummeted this year and might witness further downside. So, these stocks could be best avoided now.…

StockNews.com · Oct 19, 2022

2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…

StockNews.com · Oct 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Biotech Stock That Has Fallen Hard in 2022

Biotech stock Timber Pharmaceuticals (TMBR) is down more than 70% year-to-date. Analysts expect it to keep reporting losses over the next two years. So, will it be wise to buy the stock now? Read on to learn our view….

StockNews.com · Sep 23, 2022

3 Biotech Penny Stocks to Avoid

The biotech industry thrived during the pandemic. However, that seems to be fading as the pandemic situation has relaxed. And given the inherent volatility of penny stocks, iBio (IBIO), VistaGen Therapeutics (VTGN), and Timber Pharmaceuticals (TMBR) might be best avoided amid the broader market turmoil. Read more….

StockNews.com · Aug 23, 2022

Coverage From

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Marvell Technology Inc

41 stories

Riot Blockchain Inc

40 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.